VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW

Česká verze

Authors: Jiří Slíva
Authors place of work: Ústav farmakologie, 3. LF UK, Ruská 87,0 00 Praha 10 ¹⁰
Published in the journal: Čes. a slov. Oftal., 76, 2020, No. 4, p. 143-145
Category: Přehledová práce
doi: https://doi.org/10.31348/2020/11

Summary

The issue of macular retinal degeneration is one of the key areas of ophthalmology. Recent advances in the targeted delivery of vascular endothelial growth factor (VEGF) suppressants have significantly impacted the patient's prognosis in the form of a significant deceleration in disease progression. Some of the drugs have gradually found their use in other indications (central retinal vein occlusion or diabetic macular edema). The following text gives a brief look at the physiology of VEGF, but not only in the eye, but throughout the human body, particularly in the context of adverse effects resulting from systemic inhibition of its effects.

Keywords:

ranibizumab – bevacizumab – pharmacokinetics – adverse effects – aflibercept – VEGF – vascular endothelial growth factor – pegaptanib

Zdroje

1. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan;120(1):106–114.

2. Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF Therapy for Retinal Vein Occlusions. Curr Drug Targets. 2016;17(3):328–336.

3. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985.

4. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6(2):209.

5. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998 Mar 20;92(6):735–745.

6. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem. 2000 Jun 16;275(24):18040–18045.

7. Gong B, Liang D, Chew TG, Ge R. Characterization of the zebrafish vascular endothelial growth factor A gene: comparison with vegf-A genes in mammals and Fugu. Biochim Biophys Acta. 2004 Jan 5;1676(1):33–40.

8. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001 Mar;114(Pt 5):853–865.

9. Yang PY, Rui YC, Jin YX, Li TJ, Qiu Y, Zhang L et al. Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor expression in U937 foam cells. Acta Pharmacol Sin. 2003 Jun;24(6):610–614.

10. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999 Jul 15;19(14):5731–5740.

11. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10242–10247.

12. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001 Jun;28(2):131–138.

13. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999 Jun;5(6):623–628.

14. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K et al. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol. 2003 Jan;162(1):171–181.

15. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med. 1998 Mar;4(3):336–340.

16. Ziegler BL, Valtieri M, Porada GA, De Maria R, Müller R, Masella B et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999 Sep 3;285(5433):1553–1558.

17. Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572–584.

18. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018 May 8;2 : 13.

19. Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M et al. VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. Hypertension. 2018 Apr;71(4):638–647.

20. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018 Jun;12(6):409–425.

21. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013 Apr;97(4):454–459.

22. Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015 Mar;93(2):e154–159.

23. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014 Dec;98(12):1636–1641.

24. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017 Oct;37(10):1847–1858.

25. Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T. Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema. Retina. 2018 Sep;38(9):1801–1808.